161 related articles for article (PubMed ID: 38637772)
1. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
Zhu M; Jin M; Zhao X; Shen S; Chen Y; Xiao H; Wei G; He Q; Li B; Peng Z
BMC Med; 2024 Apr; 22(1):165. PubMed ID: 38637772
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhang N; Yu BR; Wang YX; Zhao YM; Zhou JM; Wang M; Wang LR; Lin ZH; Zhang T; Wang L
J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
4. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Edeline J; Touchefeu Y; Guiu B; Farge O; Tougeron D; Baumgaertner I; Ayav A; Campillo-Gimenez B; Beuzit L; Pracht M; Lièvre A; Le Sourd S; Boudjema K; Rolland Y; Boucher E; Garin E
JAMA Oncol; 2020 Jan; 6(1):51-59. PubMed ID: 31670746
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
Marquardt S; Kirstein MM; Brüning R; Zeile M; Ferrucci PF; Prevoo W; Radeleff B; Trillaud H; Tselikas L; Vicente E; Wiggermann P; Manns MP; Vogel A; Wacker FK
Eur Radiol; 2019 Apr; 29(4):1882-1892. PubMed ID: 30255257
[TBL] [Abstract][Full Text] [Related]
6. Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma.
Lei Z; Ma W; Si A; Zhang Y; Yang F; Yu Q; Tang H; Xiao Q; Zhou J; Wang K; Tang Y; Han T; Yin G; Chen J; Liu X; Zhao H; Yu D; Luo T; Wang Q; Yan M; Mao X; Li J; Wang K; Li J; Zeng Y; Ding D; Chen T; Wu X; Xia Y; Wang K; Guo W; Zhu G; Gao S; Hüser N; Lau WY; Song T; Cheng S; Shen F; Cheng Z
Aliment Pharmacol Ther; 2023 Sep; 58(6):611-622. PubMed ID: 37349908
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy.
Deng M; Li S; Wang Q; Zhao R; Zou J; Lin W; Mei J; Wei W; Guo R
Ann Med; 2022 Dec; 54(1):803-811. PubMed ID: 35272564
[TBL] [Abstract][Full Text] [Related]
9. First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study.
Ye Z; Zhang Y; Chen J; Wang X; Hong Y; Zhao Q
Int Immunopharmacol; 2023 Jul; 120():110344. PubMed ID: 37245298
[TBL] [Abstract][Full Text] [Related]
10. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
11. A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO).
Elias C; Zeidan YH; Bouferraa Y; Mukherji D; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
BMC Cancer; 2022 Dec; 22(1):1296. PubMed ID: 36503610
[TBL] [Abstract][Full Text] [Related]
12. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients.
Zeng ZC; Tang ZY; Fan J; Zhou J; Qin LX; Ye SL; Sun HC; Wang BL; Li D; Wang JH; Zeng MS; Guo W; Tan YS
Cancer J; 2006; 12(2):113-22. PubMed ID: 16630402
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
Luo X; Jia W; Huang Z; Li X; Xing B; Jiang X; Li J; Si A; Yang T; Gao C; Lau WY; Shen F
Oncotarget; 2017 Mar; 8(10):17246-17257. PubMed ID: 27783997
[TBL] [Abstract][Full Text] [Related]
15. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Shi GM; Huang XY; Wu D; Sun HC; Liang F; Ji Y; Chen Y; Yang GH; Lu JC; Meng XL; Wang XY; Sun L; Ge NL; Huang XW; Qiu SJ; Yang XR; Gao Q; He YF; Xu Y; Sun J; Ren ZG; Fan J; Zhou J
Signal Transduct Target Ther; 2023 Mar; 8(1):106. PubMed ID: 36928584
[TBL] [Abstract][Full Text] [Related]
16. Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
Chao J; Wang S; Wang H; Zhang N; Wang Y; Yang X; Zhu C; Ning C; Zhang X; Xue J; Zhang L; Piao M; Wang M; Yang X; Lu L; Zhao H
Cancer Immunol Immunother; 2023 Nov; 72(11):3717-3726. PubMed ID: 37787790
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma.
Franssen S; Soares KC; Jolissaint JS; Tsilimigras DI; Buettner S; Alexandrescu S; Marques H; Lamelas J; Aldrighetti L; Gamblin TC; Maithel SK; Pulitano C; Margonis GA; Weiss MJ; Bauer TW; Shen F; Poultsides GA; Marsh JW; Cercek A; Kemeny N; Kingham TP; D'Angelica M; Pawlik TM; Jarnagin WR; Koerkamp BG
JAMA Surg; 2022 Jul; 157(7):590-596. PubMed ID: 35544131
[TBL] [Abstract][Full Text] [Related]
18. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
Huang Y; Du Z; Kan A; He M; Li H; Lai Z; Wen D; Huang L; Li Q; Xu L; Shi M
Front Immunol; 2024; 15():1260191. PubMed ID: 38384459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
